TeselaGen Biotechnology, based in San Francisco, leverages artificial intelligence to accelerate the development of therapeutics, high-value chemicals, and agricultural products. The company's AI-powered platform enhances the efficiency and speed of product development cycles, addressing common challenges in site-directed mutagenesis and automating biotech R&D workflows. TeselaGen's market focus spans the biotechnology sector, including pharmaceuticals, chemicals, and agriculture.
TeselaGen has made significant strides in the biotech industry, including the launch of Built Biotechnologies, a spin-off aimed at advancing DNA manufacturing. The company's platform has been instrumental in optimizing the DBTL (Design-Build-Test-Learn) cycle, thereby elevating research and development workflows. TeselaGen's impact is evident in its ability to streamline complex processes and improve productivity in biotech innovation.
